WallStreetZenWallStreetZen

NASDAQ: MRKR
Marker Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Marker Therapeutics revenue was $6.59M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $2.3M, up 16.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRKR annual revenue was $6.6M, with 99.1% growth year-over-year.

MRKR past revenue growth

How has MRKR's revenue growth performed historically?

Company
99.06%
Industry
505.6%
Market
20.84%
MRKR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MRKR's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MRKR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

MRKR revenue history

Current Revenue
$6.6M
Current Earnings
-$10.7M
Current Profit Margin
-162.8%

Be the first to know when MRKR announces revenue.

MRKR Revenue History By Year

MRKR Yearly RevenueMRKR RevenueMRKR ChangeMRKR Revenue Growth
2024-12-31$6.59M$3.28M+99.06%
2023-12-31$3.31M-$202.41k-5.76%
2022-12-31$3.51M$2.27M+182.96%
2021-12-31$1.24M$774.93k+166.01%
2020-12-31$466.79k$253.59k+118.95%
2019-12-31$213.19k$7.20k+3.50%
2018-12-31$205.99k$22.93k+12.53%
2017-12-31$183.06kN/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A

1 of 1

Marker Therapeutics Revenue FAQ

What was MRKR's revenue last quarter?

On Invalid Date, Marker Therapeutics (NASDAQ: MRKR) reported Q4 2024 revenue of $2.25 million up 113.13% year over year. In the same quarter last year, Marker Therapeutics's revenue was $1.06 million.

What was Marker Therapeutics's revenue in 2024?

Marker Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $6.59 million, a 99.06% increase year over year.

How much does Marker Therapeutics make in a day?

Based on Marker Therapeutics annual revenue for the past five years, MRKR makes an average of $8,287.26 per day.

What was Marker Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Marker Therapeutics's revenue has grown 99.06% year over year. This is 406.54 percentage points lower than the US Biotechnology industry revenue growth rate of 505.6%. Marker Therapeutics's revenue in the past year totaled $6.59 million.

How much does Marker Therapeutics make in a year?

Marker Therapeutics's revenue by year for the past five years is:
  • Marker Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $6.59 million, a 99.06% increase year over year.
  • Marker Therapeutics's annual revenue for Dec 31, 2023 was $3.31 million, a 5.76% decrease from 2022.
  • Marker Therapeutics's annual revenue for 2022 was $3.51 million, a 182.96% increase from 2021.
  • Marker Therapeutics's annual revenue for 2021 was $1.24 million, a 166.01% increase from 2020.
  • Marker Therapeutics's annual revenue for 2020 was $466.79 thousand, a 118.95% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.